CD274 and cancer: By targeting the key immune checkpoints involved in the relationship between cancer and the immune system, including the programmed cell death receptor 1 (PD-1), its ligand (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4), these drugs prevent immunosuppressive interactions that lead to immune escape and restore the killing activity of immune cells towards tumor cells [4].